Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 7:15 PM
Ignite Modification Date:
2025-12-24 @ 7:15 PM
NCT ID:
NCT02335203
Eligibility Criteria:
Inclusion Criteria:
* Patient at the Women and Infants Program in Women's Oncology
* Biopsy-proven complex atypical hyperplasia or grade 1 or grade 2 endometrial adenocarcinoma with endometrioid histology
* Disease clinically confined to the uterus (no physical exam findings or imaging to suggest extrauterine disease)
* Ages 18 and older
* Plan for hysterectomy at Women and Infants Hospital of Rhode Island
* Able to read English or Spanish
* Able to give informed consent for involvement in the study
Exclusion Criteria:
* Allergic to medroxyprogesterone acetate
* Known sensitivity to any component of depot medroxyprogesterone acetate
* History of breast cancer, hepatic disease, uncontrolled hypertension, osteoporosis or strong osteoporotic risk factors including anorexia nervosa, rheumatoid arthritis and chronic glucocorticoid use
* Treatment with any progesterone or progesterone analogue in past 12 months
Healthy Volunteers:
False
Sex:
FEMALE
Minimum Age:
18 Years
Study:
NCT02335203
Study Brief:
Protocol Section:
NCT02335203